Sanofi SA (EPA:SAN) has been given a €97.00 ($114.12) target price by Berenberg Bank in a report issued on Thursday. The brokerage currently has a “neutral” rating on the stock. Berenberg Bank’s price target would suggest a potential upside of 22.75% from the stock’s previous close.
Several other equities analysts also recently commented on SAN. HSBC Holdings plc set a €81.00 ($95.29) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a research note on Wednesday, August 30th. J P Morgan Chase & Co set a €85.00 ($100.00) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a research note on Thursday, September 14th. Jefferies Group LLC set a €86.00 ($101.18) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a research note on Monday, September 18th. Citigroup Inc set a €88.00 ($103.53) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a research note on Friday, October 6th. Finally, Deutsche Bank AG set a €96.00 ($112.94) price objective on shares of Sanofi SA and gave the company a “buy” rating in a research note on Wednesday, October 18th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of €87.24 ($102.63).
Shares of Sanofi SA (EPA SAN) traded down €0.52 ($0.61) during midday trading on Thursday, reaching €79.02 ($92.96). 1,860,000 shares of the company were exchanged, compared to its average volume of 1,850,000. Sanofi SA has a 12-month low of €70.94 ($83.46) and a 12-month high of €92.97 ($109.38).
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/11/04/sanofi-sa-san-given-a-97-00-price-target-by-berenberg-bank-analysts.html.
About Sanofi SA
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi SA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi SA and related companies.